Celltrion Pharm, Inc.

Total Valuation

Celltrion Pharm, Inc. carries a market capitalization of 1.81T, placing it among publicly traded companies globally. Its enterprise value stands at 2.45T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Celltrion Pharm, Inc. currently has 44.26M shares outstanding.

Valuation Ratios

Celltrion Pharm, Inc. trades at a trailing price-to-earnings ratio of 60.31. The price-to-sales ratio is 4.37, and the price-to-book ratio stands at 13.62.

Enterprise Valuation

On an enterprise value basis, Celltrion Pharm, Inc. trades at an EV/EBITDA multiple of 42.12 and an EV/FCF ratio of 22.64. The EV/Sales ratio of 4.41 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 42.12 provides insight into valuation relative to core operating earnings.

Financial Position

Celltrion Pharm, Inc. maintains a current ratio of 1.65, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.93, indicating elevated leverage, while an interest coverage ratio of 8.98 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Celltrion Pharm, Inc. posts a return on equity of 23.76 and a return on invested capital of 7.65.

Taxes

Over the trailing twelve months, Celltrion Pharm, Inc. has paid 11.81B in income taxes, reflecting an effective tax rate of 22.69.

Stock Price Statistics

Celltrion Pharm, Inc.'s stock has declined approximately -22.87335% over the past 52 weeks. The 50-day moving average sits at 47,257.00, while the 200-day moving average is 57,886.64.

Income Statement

Over the trailing twelve months, Celltrion Pharm, Inc. generated 556.00B in revenue and converted that into 40.25B in net income, yielding earnings per share of 908.63. EBITDA reached 58.26B, while operating income came in at 58.26B.

Balance Sheet

Celltrion Pharm, Inc. holds 133.91B in cash and equivalents against 160.58B in total debt, resulting in a net debt position of 85.21B. Total book value stands at 178.23B, with working capital of 188.86B providing operational flexibility.

Cash Flow

Celltrion Pharm, Inc. produced 77.88B in operating cash flow over the past twelve months. After subtracting -25.47B in capital expenditures, free cash flow totaled 52.41B - equivalent to 1,183.33 per share.

Margins

Celltrion Pharm, Inc. operates with a gross margin of 30.52, reflecting its pricing power and cost economics. The operating margin of 10.48 and net profit margin of 7.24 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Celltrion Pharm, Inc.'s most recent stock split took place on December 29, 2025 with a 50:51 split ratio.

Scores

Celltrion Pharm, Inc. posts an Altman Z-Score of 6.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.